The decision was supported by a randomised, six-week, placebo-controlled trial involving 316 adolescent subjects.

The European Commission (EC) has approved Danish CNS specialist Lundbeck (LUND: CO) and Otsuka Europe’s Rxulti ...

The IFPA Forum 2025 will unite stakeholders from across the Americas to address the urgent challenges faced by individuals ...

Caliber recently launched 4 digital solutions that further strengthen its portfolio and also position the company at the ...

Otsuka Pharmaceutical Europe and Lundbeck have announced that the European Commission has approved Rxulti (brexpiprazole) for ...

Otsuka Pharmaceutical Europe Ltd. (Otsuka) and H. Lundbeck A/S (Lundbeck) today announced that the European Commission (EC) has approved Rxulti® (brexpiprazole) for the treatment of schizophrenia in ...

Vadodara: Alembic Pharma has announced that the United States Food and Drug Administration (USFDA) has concluded an ...

Obesity and pharmacology experts are warning about hidden safety risks and efficacy issues for many types of medications in ...

Compass Pathways Plc (NASDAQ:CMPS) reported its fourth-quarter 2024 earnings, meeting its earnings per share (EPS) forecast of -0.63, with no revenue reported. Despite the lack of revenue, the company ...

Compass Pathways Plc (NASDAQ:CMPS) reported its fourth-quarter 2024 earnings, meeting its earnings per share (EPS) forecast of -0.63, with no revenue reported. Despite the lack of revenue, the ...